Tunlametinib: First Approval
Article in Drugs (July 2024)
The most recent citing publications are shown below. View all 3 publications that cite this research output on Dimensions.
Inhibiting the Extracellular Signal-regulated Kinase 1/2 (ERK1/2) Cascade in Cancer and the Heart: for Better or Worse, in Sickness and Health?
Article in International Journal of Drug Discovery and Pharmacology (May 2024)
A phase II study of efficacy and safety of the MEK inhibitor tunlametinib in patients with advanced NRAS-mutant melanoma
Article in European Journal of Cancer (March 2024)